Commit Biologics

Commit Biologics is a private, pre-clinical stage biotech leveraging deep academic expertise in complement biology to develop a new class of targeted immunotherapies. Its core BiCE™ platform uses single-domain antibodies to engage the C1q protein, aiming to overcome limitations of current antibody and cell-based therapies by potently activating the complement cascade against tumor or autoimmune cells. The company is backed by venture investors, has achieved non-human primate proof-of-concept, and is advancing its platform towards clinical development for oncology and autoimmune indications.

Bispecific Complement Engaging (BiCE™) platform using single-domain antibodies to bind C1q and target antigens, directing potent complement-mediated killing of specific cells.

Commit operates in the emerging field of targeted complement activation, competing with a small set of biotechs exploring similar concepts. It faces broader competition from established modalities like ADCs, bispecific T-cell engagers, and CAR-Ts. Its differentiation lies in its specific C1q-engaging mechanism and strong academic foundation in complement biology.